Drug Trial Radar · NCT07943585
A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,260
Planned (sponsor's estimate)
Start
Nov 24, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Reinovax Biologics Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.
Conditions
- Pneumococcal Infectious Disease
Interventions
Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24Biological
Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL
PPSV23Biological
One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).Time frame: 0~30 days after vaccination
- Proportional participants with the MOPA titer rise of 4-fold or higherTime frame: 0~30 days after vaccination
- Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).Time frame: 0~30 days after vaccination
- Incidence of adverse eventsTime frame: 0-30 minutes after vaccination
- Incidence of solicited adverse eventsTime frame: 0-7 days after vaccination
- Incidence of unsolicited adverse eventsTime frame: 0-30 days after vaccination
- Incidence of serious adverse events (SAE)Time frame: 0-6 months after vaccination
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Center for Disease Control and Prevention
Shanghai, China
Hunan Center for Disease Control and Prevention
Changsha, Hunan, China
Baoshan Second People's Hospital
Baoshan, Yunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.